Document:

Technology
      Transfer Contract

    

    Name:
      Prulifloxacin (material and tablets) Technology Transfer

    

    Transferee:
      (Party
      A) Nantong Cyton Pharmaceutical Co., Ltd.

    Transferor
      :( Party
      B) Nanjing Suji Bio-medicine Research and Development Co, .Ltd.

    

    Date:
      November 2003

    Location:
      Nanjing

    Term
      of Validity:
      Before
      30th-October-2007

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    Technology
      Transfer Contract

     

    Transferee
      (Party A) Nantong Cyton Pharmaceutical Co., Ltd.

     

    Contact
      person : Sun Xiaorong

     

    Address:
      Tongzhou Economical Development Area Nantong Jiangsu Province.

     

    Telephone:0513-6088763
      Fax: 0513-6519322

     

    E-mail
      Box: sun_xr@souhu.com

     

    Transferor:
      ( Party B ) Nanjing Suji Bio-medicine Research and Development
      Co,.Ltd.

     

    Contact
      person : Wang Lei

     

    Address:
      Nanjing Jiangnin Development Area Scien-technology Center Building 2

     

    Telephone:025-52107633
      Fax: 025-52101493

     

    E-mail
      Box: njsuji@jsmail.com.cn

     

    This
      contract is entered into between the parties concerned on the basis of equality
      and mutual benefit to develop business on terms and conditions mutually agreed
      upon as follows:

     

    Article
      1:
      The
      content of technology secret transferred by Party B to Party A 

    

    
      	
              1.

            	
              Technology
                secret range : Party B shall agree that technology, technology information
                and clinical approvals of the new drug Prulifloxacin be transferred
                to
                Party A. 

            

    

    

    
      	
              2.

            	
              Technology
                specification: Comply with SDA < Examination and Approval for New
                medicine> 

            

    

    

    
      
        
          	3.	
                  Degree
                    of industrialized development of technology secret
                    :Good.

                

        

      

    

    
       

    

    Article
      2
      To
      ensure Party A shall perform the technology secret effectively, Party B shall
      provide Party A with application materials of class 2 western medicine. These
      materials shall include the followings:

     

    
      
        
          	1)	
                  Review
                    :1. New medicine name 2. Certificates and information. 3. Purpose
                    and
                    basis. 4. Conclusion and evaluation on the main research results.
                    5.
                    Medicine instruction and recent reference. 6. Package, design
                    samples.

                

        

      

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      
        
          	2)	
                  Pharmacological
                    material: 7. Pharmacology study review. 8. Material producing
                    technology
                    study and reference; formula of the medicine.9. Experimental
                    information
                    and reference confirming the medicine chemical structure or composition.
                    10. Experimental information and reference of quality research.
                    11.
                    Medicine draft. 12. Sample test report. 13. The derive and quality
                    standard of pharmaceutical recipients. 14. Stableness research
                    experimental information and reference. 15. Basis of selecting
                    package
                    material and vessels holding the medicine and their quality standard.
                    

                

        

      

    

    

    
      
        
          	3)	
                  Toxicology
                    Materials of the medicine: 16. Pharmacology and toxicology study
                    review.17. The main pharmacology study experimental information
                    and
                    reference. 18. General Pharmacological study experimental information
                    and
                    reference. 19. Acute toxicity test information and reference.
                    20.
                    Long-term toxicity test information and reference. 21. The test
                    of
                    Hypersentivity, hemolysis and safety of delivering the medicine
                    locally
                    and systemically and reference. 23. Mutatiuon effect test information
                    and
                    reference. 24. Reproductive toxicity test information and reference.
                    25.
                    Cancer effect test information and
                    reference.

                

        

      

    

    

    
      
        
          	4)	
                  Clinical
                    Information:

                

        

      

    

    

    28.
      Relevant clinical study information reviews inside and outside the country.
      29.
      Clinical research plan and design. 30. Clinical researcher
      instructions.

    

    Article
      3:
      Party
      summit the technology information as following requires:

    

    
      	1:	
              Deadline:
                Before 30-April-2004

            

    

     

    
      	2:	
              Location
                :Nanjing

            

    

     

    
      	3:	
              Method:
                Inspection and acceptance by
                experts.

            

    

    

    Article
      4:
      Party B
      implemented or transferred the technology secret as followings before the
      contract coming to effect.

     

    
      
        
          	1.	
                  Administration
                    of the technology secret: PartyBFinished information
                    1,2,3,4,5,5,7,8,9,10,12,13,14,15,18,19,20,21,22,23,24,25,28,29
                    and 30
                    before May 2003 in
                    Nanjing.

                

        

      

    

    

    
      
        
          	2.	
                  Transfer
                    of the technology secret:
                    Vacant

                

        

      

    

    

    Article
      5:
      Party A
      shall administrate the technology secret as followings:

    

    
      
        
          	1.	
                  Administration
                    scope: Party A may arrange the scope of administration by itself.
                    But the
                    administration of the technology secret shall not invade other
                    technologies of Party B.

                

        

         

      

    

    
      
        
          	
                  2.

                	
                  Administration method: Party A shall administrate the technology
                    with
                    instruction by staffs from Party B. Party A shall administrate
                    the
                    technology independently after producing three batches of qualified
                    products.

                

        

      

    

    

    
      
        
          	3.	
                  Administration
                    validity: Administrate gradually on accordance with the payment
                    of the
                    technology transfer
                    expense.

                

        

      

    

    

    Article
      6: Party B shall undertake the practicability, reliability, and guarantee that
      the technology secret does not invade the third person’s legal right. If a third
      person complains Party A of invading technology secret, Party B shall bear
      the
      expense due to invading the right.

     

    Article
      7: Either party shall inform the other party to release the contract within
      10
      days after the technology secret has been publicized by others during
      administration of the contract. If the Party fails to inform the other party
      in
      time, the party shall compensate for the other party. 

    

    Article
      8:
      Obligation of Confidentiality

    

    Party
      A:

    

    
      
        
          	1.	
                  Confidential
                    content: technology information and relevant experimental data
                    of the new
                    drug Prulifloxacin.

                

        

      

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      
        
          	2.	
                  Personnel
                    : Relevant management staffs, research and development personnel
                    in Party
                    A.

                

        

      

    

    

    
      
        
          	3.	
                  Confidential
                    Term: on accordance with validity regulation in new medicine
                    certificate
                    and manufacture
                    approval.

                

        

      

    

    

    
      
        
          	4.	
                  Liability
                    of disclosing the secret: The two sides shall neither disclose
                    the
                    relevant information, technology, information and material to
                    others nor
                    cooperates with a third side. The Party shall be investigated
                    legal
                    liability if it violates the
                    contract.

                

        

      

    

    

    Party
      B;

    

    
      	1:	
              Confidential
                content: technology information and relevant experimental data of
                the new
                drug Prulifloxacin.

            

    

    

    
      	2.	
              Personnel
                : Relevant management staffs, research and development personnel
                in Party
                B.

            

    

    

    
      	3.	
              Confidential
                Term: on accordance with validity regulation in new medicine certificate
                and manufacture approval.

            

    

    

    
      	4.	
              Liability
                of disclosing the secret: The two sides shall neither disclose the
                relevant information, technology, information and material to others
                nor
                cooperates with a third side. The Party shall be investigated legal
                liability if it violates the
                contract.

            

    

    

    Article
      9:
      Both
      sides Party B shall inform Party A and protect Party A’s benefit if the
      technology secret is publicized as a patent or other form during the validity
      of
      the contract. Party A shall have the right to continue using the patent assuming
      Party B attains the patent of the technology.

    

    Article
      10:
      Party B
      shall provide Party A with the following technology service and instruction
      to
      make Party A effectively administrate the technology secret.

    

    
      	
              1.

            	
              Technology
                service and instruction: Party B shall be responsible for the study
                and
                producing of new drug Prulifloxacin.(Including technology, approval,
                new
                medicine certificate and so on)

            

    

    

    
      
        
          	2.	
                  Methods
                    of technology service and instruction: Party B shall be responsible
                    for
                    instructing Party A to master the producing technology and producing
                    three
                    batches qualified
                    products.

                

        

      

    

    

    Article
      11
      The
      transfer expense paid by Party A is 9,000,000 Yuan. Term of payment is as
      followings:

    

    
      	
              1)

            	
              Party
                A shall pay the first term transfer expense for 4,500,000 Yuan within
                10
                days after the contract coming into
                effect.

            

    

    

    
      	
              2)

            	
              Party
                A shall pay 3,505,000 yuan within 10 days after examination and
                acceptance.

            

    

    

    
      	
              3)

            	
              Party
                A shall pay 545,000 yuan within 10 days after acquiring clinical
                research
                approval of the medicine.

            

    

    

    
      	
              4)

            	
              Party
                A shall pay 450,000 yuan within 10 days after receiving information
                from
                Party B. If Party A has prepared manufacturing field, the payment
                shall be
                performed as following: Party A shall pay 450,000 yuan within 10days
                after
                manufacturing three batches qualified
                products.

            

    

    

    The
      bank
      name, address and account of Party B

     

    Bank:
      Huaxia Bank Nanjing Hunan Road Branch

     

    Address:
      Nanjing jiangning economic development area shengtai road.

     

    Account:
      077700819400013526

    

    Article
      12:
      The two
      sides agree that the examination and acceptance shall be performed on the basis
      of the following standard and methods.

    

    
      	
              1.

            	
              Acquire
                the approval of the provincial SDA new medicine approval. Report
                to SDA
                before 31 April 2004.

            

    

    

    
      	
              2.

            	
              Acquire
                state new medicine clinical research approval before 31 December
                2005.

            

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      	
              3.

            	
              Attain
                state new medicine certificate and manufacturing
                approval.

            

    

    

    Article
      13
      Party A
      shall administrate the technology secret within 10 days after the contract
      coming into effect. Party A shall inform Party B if Party A fails to
      administrate in time.

    

    Article
      14:
      The two
      sides agree that neither of the two sides shall limit the technology contest
      and
      processing in any of the following ways:

    

    
      	
              1.

            	
              Not
                paying for transfer expense or submit relevant information confirmed
                in
                the contract.

            

    

    

    
      	
              2.

            	
              Not
                arranging professional technology personnel to cooperate with the
                other
                side

            

    

    

    
      	
              3.

            	
              Manage
                staffs not responsible

            

    

    

    Article
      15:

     

    The
      two
      sides agree that

    

    
      	
              1.

            	
              Party
                A shall have the right to improve the technology secret transferred
                by
                Party B. Any substantial or innovative technology achievements due
                to
                Party A’s improvement shall belong to Party A. Relevant benefits shall be
                distributed as following: Party A’s innovative technology improvement
                results and the benefits belong to Party
                A.

            

    

    

    
      	
              2.

            	
              Party
                B shall have the right to improve the technology secret transferred.
                Any
                substantial or innovative technology achievements due to Party B’s
                improvement shall belong to Party B. Relevant benefits shall be
                distributed as following: Party A shall pay for the transfer expense
                if
                Party A requires the new improved innovative technology. The amount
                of the
                payment shall be consulted by the two
                sides.

            

    

    

    Article16.
      Any
      modification of the contract shall be agreed by the two sides and be confirmed
      in written form. Either party shall raise the request of modifying rights and
      obligations to the other side when anyone of the following issues takes place:
      The other Party shall answer the request within 10 days. It shall be considered
      agreement on the request if the other Party fails to answer the request in
      time.

    

    
      	
              1.

            	
              Either
                party fails to fulfill obligations without full reasons exceeding
                the term
                confirmed.

            

    

    

    
      	
              2.

            	
              Either
                party refuses to fulfill obligations desperately or for some
                excuses.

            

    

    

    
      	
              3.

            	
              Either
                party’s business condition changes substantially and is unable to
                implement the technology secret.

            

    

    

    Article
      17:
      The two
      sides confirm that each party shall take violation liability as
      followings:

    

    
      	
              1.

            	
              Party
                A shall pay transfer expense in time . Party A shall pay the one
                ten-thousandth of penalty for breach the contract if Party A violates
                Article 11 in the contract. Party B shall have the right to terminate
                the
                contract and transfer the technology to the third Party if Party
                A fails
                to pay after receiving demand of payment in written form from Party
                B.
                Party B shall have the right not to return the transfer expense paid
                by
                Party A.

            

    

    

    
      	
              2.

            	
              Party
                B shall pass the initial examination of provincial Bureau of Drug
                Surveillance before 30 April 2004 and then summit to SDA. Party B
                shall
                attain the new medicine certificate before 30 December 2005. The
                transfer
                expense shall be subtracted by one-thousand of the total amount every
                exceeding month. Party B shall return the payment from Party A if
                the
                failure of application is due to
                technology.

            

    

    

    
      	
              3.

            	
              Either
                party shall pay 10% of transfer expense to the other party if it
                violates
                other regulations except Article 2.

            

    

    

    Article
      18
      The two
      sides confirm that Party A shall appoint Sun Xiaorong as the contact person,
      whereas Party B shall appoint Wang Lei as the contact person in the term of
      validity. The contact persons shall take the following
      responsibilities:

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      	
              1.

            	
              Record
                the processing of the work.

            

    

    

    
      	
              2.

            	
              Solve
                the problems in the research and development
                work.

            

    

    

    
      	
              3.

            	
              Finish
                periodical tarattain in time.

            

    

    

    Either
      Party shall inform the other party in written form if it changes the contact
      person. The party which fails to inform the other party in time shall be liable
      for any loss caused by the failure.

    

    Article
      19
      The
      contract may be released assume any issue arises:

    

    
      	
              1.

            	
              Force
                majeure

            

    

    

    
      	
              2.

            	
              Failure
                of producing on the technology due to Party A’s failure in providing
                manufacture certificate or other important
                affairs.

            

    

    

    Article
      20
      The two
      parties agree that all disputes, controversies, claims or differences arising
      between the two parties hereto shall be settled through friendly consultation
      between two parties hereto. Where the disputes cannot be settled through
      negotiations, it shall be prosecuted to the local court legally.

    

    Article
      21
      The two
      parties confirm that the relevant terms in the contract are as
      following:

     

    SDA
      :
      State Drug Administration.

    

    Article
      22 

    

    
      	
              1.

            	
              Technology
                evaluation report: None.

            

    

    

    
      	
              2.

            	
              Technology
                standard and regulation: None

            

    

    

    
      	
              3.

            	
              Initial
                design and technology documents:
                None.

            

    

    

    
      	
              4.

            	
              Other
                documents: None.

            

    

    

    Article
      23:
      The two
      sides agree that other affairs not included in hereof shall be made into
      additional regulations through friendly consultation.

    

    Article
      24:
      The
      contract shall be signed in sextuplicate. 

    

    Article
      25:
      The
      contract shall come into effect after the contract is made and signed by the
      Parties hereto.

    

    Party
      A

    Nantong
      Cyton Pharmaceutical. Co.,ltd

    Representative
      :

    

    Party
      B

    Nanjing
      Suji Bio-pharmaceutical research and development Co., Ltd.

    Representative:

    

    Date
      30
      November 2003No
      xyj
      2004/1/30/2

     

    Technology
      Transfer Contract

    

    Name:
      Cisatracurium Besylate Technology Transfer

    

    Transferee:
      (Party
      A) Nantong Cyton Pharmaceutical Co., Ltd.

     

    Transferor
      :( Party
      B) Nanjing Suji Bio-medicine Research and Development Co., Ltd.

    

    Date:
      January
      2004

     

    Location:
      Nanjing

     

    Term
      of Validity:
      30th-December-2006

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Technology
      Transfer Contract

     

    Transferee
      (Party A) Nantong Cyton Pharmaceutical Co., Ltd.

     

    Contact
      person : Sun Xiaorong

     

    Address:
      Tongzhou Economical Development Area Nantong Jiangsu Province.

     

    
      	
              Telephone:0513-6088763

            	
              Fax:
                0513-6519322

            

    

     

    E-mail
      Box: sun_xr@souhu.com

     

    Transferor:
      ( Party B ) Nanjing Suji Bio-medicine Research and Development Co.,
      Ltd.

     

    Contact
      person : Wang Lei

     

    Address:
      Nanjing Jiangnin Development Area Scien-technology Center Building 2

     

    
      	
              Telephone:025-52107633

            	
              Fax:
                025-52101493

            

    

     

    E-mail
      Box: njsuji@jsmail.com.cn

     

    This
      contract is entered into between the parties concerned on the basis of equality
      and mutual benefit to develop business on terms and conditions mutually agreed
      upon as follows: 

    Article
      1:
      The
      content of technology secret transferred by Party B to Party A 

    
      	
              1.

            	
              Technology
                secret range : Party B shall agree that technology, technology information
                and clinical approvals of the new drug Cisatracurium Besylate be
                transferred to Party A. 

            

    

    
      	
              2.

            	
              Technology
                specification: Comply with SDA < Examination and Approval for New
                medicine> 

            

    

    
      	
              3.

            	
              Degree
                of industrialized development of technology secret
                :Good.

            

    

    Article
      2
      To
      ensure Party A shall perform the technology secret effectively, Party B shall
      provide Party A with application materials of class 2 western medicine. These
      materials shall include the followings:

    
      	 	
              1)

            	
              Review
                :1. New medicine name 2.Certificates and information. 3. Purpose
                and
                basis. 4. Conclusion and evaluation on the main research results.
                5.
                Medicine instruction and recent reference. 6. Package, design
                samples.

            

    

    
      	 	
              2)

            	
              Pharmacological
                material: 7. Pharmacology study review. 8. Material producing technology
                study and reference; formula of the medicine.9. Experimental information
                and reference confirming the medicine chemical structure or composition.
                10. Experimental information and reference of quality research. 11.
                Medicine draft. 12. Sample test report. 13. The derive and quality
                standard of pharmaceutical recipients. 14. Stableness research
                experimental information and reference. 15. Basis of selecting package
                material and vessels holding the medicine and their quality standard.
                

            

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	 	
              3)

            	
              Toxicology
                Materials of the medicine: 16. Pharmacology and toxicology study
                review.
                17. The main pharmacology study experimental information and reference.
                18. General Pharmacological study experimental information and
                reference.19.Acute toxicity test information and reference. 20. Long-term
                toxicity test information and reference. 21. The test of Hypersentivity,
                hemolysis and safety of delivering the medicine locally and systemically
                and reference. 23. Mutatiuon effect test information and reference.
                24.
                Reproductive toxicity test information and reference. 25. Cancer
                effect
                test information and reference.

            

    

    
      	 	
              4)

            	
              Clinical
                Information

            

    

    28.
      Relevant clinical study information reviews inside and outside the country.
      29.
      Clinical research plan and design. 30. Clinical researcher
      instructions.

    Article
      3:
      Party
      summit the technology information as following requires:

    1:
      Deadline: Before 30-May-2004

    2:
      Location :Nanjing

    3:
      Method: Inspection and acceptance by experts.

    Article
      4:
      Party B
      implemented or transferred the technology secret as followings before the
      contract coming to effect.

    
      	 	
              1.

            	
              Administration
                of the technology secret: Party B Finished information
                1,2,3,4,5,5,7,8,9,10,12,13,14,15,18,19,20,21,22,23,24,25,28,29 and
                30
                before May 2003 in Nanjing.

            

    

    
      	 	
              2.

            	
              Transfer
                of the technology secret: Vacant

            

    

    Article
      5:
      Party A
      shall administrate the technology secret as followings:

    
      	 	
              1.

            	
              Administration
                scope: Party A may arrange the scope of administration by itself.
                But the
                administration of the technology secret shall not invade other
                technologies of Party B.

            

    

    
      	 	
              2.

            	
              Administration
                method: Party A shall administrate the technology with instruction
                by
                staffs from Party B. Party A shall administrate the technology
                independently after producing three batches of qualified
                products.

            

    

    
      	 	
              3.

            	
              Administration
                validity: Administrate gradually on accordance with the payment of
                the
                technology transfer expense.

            

    

    Article
      6: Party B shall undertake the practicability, reliability, and guarantee that
      the technology secret does not invade the third person’s legal right. If a third
      person complains Party A of invading technology secret, Party B shall bear
      the
      expense due to invading the right.

    Article
      7: Either party shall inform the other party to release the contract within
      10
      days after the technology secret has been publicized by others during
      administration of the contract. If the Party fails to inform the other party
      in
      time, the party shall compensate for the other party. 

    Article
      8:
      Obligation of Confidentiality

    Party
      A:

    
      	
              1.

            	
              Confidential
                content: technology information and relevant experimental data of
                the new
                drug Cisatracurium Besylate.

            

    

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
              2.

            	
              Personnel
                : Relevant management staffs, research and development personnel
                in Party
                A.

            

    

    
      	
              3.

            	
              Confidential
                Term: on accordance with validity regulation in new medicine certificate
                and manufacture approval.

            

    

    
      	
              4.

            	
              Liability
                of disclosing the secret: The two sides shall neither disclose the
                relevant information, technology, information and material to others
                nor
                cooperates with a third side. The Party shall be investigated legal
                liability if it violates the
                contract.

            

    

    Party
      B;

    1:
      Confidential content: technology information and relevant experimental data
      of
      the new drug Cisatracurium Besylate.

    2.
      Personnel : Relevant management staffs, research and development personnel
      in
      Party B.

    3.Confidential
      Term: on accordance with validity regulation in new medicine certificate and
      manufacture approval.

    4.
      Liability of disclosing the secret: The two sides shall neither disclose the
      relevant information, technology, information and material to others nor
      cooperates with a third side. The Party shall be investigated legal liability
      if
      it violates the contract.

    Article
      9:
      Both
      sides Party B shall inform Party A and protect Party A’s benefit if the
      technology secret is publicized as a patent or other form during the validity
      of
      the contract. Party A shall have the right to continue using the patent assuming
      Party B attains the patent of the technology.

    Article
      10:
      Party B
      shall provide Party A with the following technology service and instruction
      to
      make Party A effectively administrate the technology secret.

    
      	
              1.

            	
              Technology
                service and instruction: Party B shall be responsible for the study
                and
                producing of new drug Cisatracurium Besylate.(Including technology,
                approval, new medicine certificate and so
                on)

            

    

    
      	
              2.

            	
              Methods
                of technology service and instruction: Party B shall be responsible
                for
                instructing Party A to master the producing technology and producing
                three
                batches qualified products.

            

    

    Article
      11
      The
      transfer expense paid by Party A is 5,000,000 Yuan. Term of payment is as
      followings:

    
      	
              1)

            	
              Party
                A shall pay 3,500,000 Yuan within 10 days after the contract coming
                into
                effect.

            

    

    
      	
              2)

            	
              Party
                A shall pay 1,500,000 yuan within 10 days after examination and
                acceptance.

            

    

    
      	
              3)

            	
              Party
                A shall pay 1,000,000 yuan within 10 days after acquiring clinical
                research approval of the medicine.

            

    

    The
      bank
      name, address and account of Party B

    Bank:
      Huaxia Bank Nanjing Hunan Road Branch

    Address:
      Nanjing jiangning economic development area shengtai road.

    Account:
      077700819400013526

    Article
      12:
      The two
      sides agree that the examination and acceptance shall be performed on the basis
      of the following standard and methods.

    
      	
              1.

            	
              Acquire
                the approval of the provincial SDA new medicine approval. Report
                to SDA
                before 31 May 2004.

            

    

    
      	
              2.

            	
              Acquire
                state new medicine clinical research approval before 31 June
                2006.

            

    

    
      	
              3.

            	
              Attain
                state new medicine certificate and manufacturing
                approval.

            

    

    Article
      13
      Party A
      shall administrate the technology secret within 10 days after the contract
      coming into effect. Party A shall inform Party B if Party A fails to
      administrate in time.

    Article
      14:
      The two
      sides agree that neither of the two sides shall limit the technology contest
      and
      processing in any of the following ways:

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    
      	
              1.

            	
              Not
                paying for transfer expense or submit relevant information confirmed
                in
                the contract.

            

    

    
      	
              2.

            	
              Not
                arranging professional technology personnel to cooperate with the
                other
                side

            

    

    
      	
              3.

            	
              Manage
                staffs not responsible

            

    

    Article
      15:

    The
      two
      sides agree that

    
      	
              1.

            	
              Party
                A shall have the right to improve the technology secret transferred
                by
                Party B. Any substantial or innovative technology achievements due
                to
                Party A’s improvement shall belong to Party A. Relevant benefits shall be
                distributed as following: Party A’s innovative technology improvement
                results and the benefits belong to Party
                A.

            

    

    
      	
              2.

            	
              Party
                B shall have the right to improve the technology secret transferred.
                Any
                substantial or innovative technology achievements due to Party B’s
                improvement shall belong to Party B. Relevant benefits shall be
                distributed as following: Party A shall pay for the transfer expense
                if
                Party A requires the new improved innovative technology. The amount
                of the
                payment shall be consulted by the two
                sides.

            

    

    Article16.
      Any
      modification of the contract shall be agreed by the two sides and be confirmed
      in written form. Either party shall raise the request of modifying rights and
      obligations to the other side when anyone of the following issues takes place:
      The other Party shall answer the request within 10 days. It shall be considered
      agreement on the request if the other Party fails to answer the request in
      time.

    
      	
              1.

            	
              Either
                party fails to fulfill obligations without full reasons exceeding
                the term
                confirmed.

            

    

    
      	
              2.

            	
              Either
                party refuses to fulfill obligations desperately or for some
                excuses.

            

    

    
      	
              3.

            	
              Either
                party’s business condition changes substantially and is unable to
                implement the technology secret.

            

    

    Article
      17:
      The two
      sides confirm that each party shall take violation liability as
      followings:

    
      	
              1.

            	
              Party
                A shall pay transfer expense in time . Party A shall pay the one
                ten-thousandth of penalty for breach the contract if Party A violates
                Article 11 in the contract. Party B shall have the right to terminate
                the
                contract and transfer the technology to the third Party if Party
                A fails
                to pay after receiving demand of payment in written form from Party
                B.
                Party B shall have the right not to return the transfer expense paid
                by
                Party A.

            

    

    
      	
              2.

            	
              Party
                B shall pass the initial examination of provincial Bureau of Drug
                Surveillance before 31 May 2004 and then summit to SDA. Party B shall
                attain the new medicine certificate before 30 June 2006. The transfer
                expense shall be subtracted by one-thousand of the total amount every
                exceeding month. Party B shall return the payment from Party A if
                the
                failure of application is due to
                technology.

            

    

    
      	
              3.

            	
              Either
                party shall pay 10% of transfer expense to the other party if it
                violates
                other regulations except Article 2.

            

    

    Article
      18
      The two
      sides confirm that Party A shall appoint Sun Xiaorong as the contact person,
      whereas Party B shall appoint Wang Lei as the contact person in the term of
      validity. The contact persons shall take the following
      responsibilities:

    
      	
              1.

            	
              Record
                the processing of the work.

            

    

    
      	
              2.

            	
              Solve
                the problems in the research and development
                work.

            

    

    
      	
              3.

            	
              Finish
                periodical tarattain in time.

            

    

    Either
      Party shall inform the other party in written form if it changes the contact
      person. The party which fails to inform the other party in time shall be liable
      for any loss caused by the failure.

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    Article
      19
      The
      contract may be released assume any issue arises:

    
      	
              1.

            	
              Force
                majeure

            

    

    
      	
              2.

            	
              Failure
                of producing on the technology due to Party A’s failure in providing
                manufacture certificate or other important
                affairs.

            

    

    Article
      20
      The two
      parties agree that all disputes, controversies, claims or differences arising
      between the two parties hereto shall be settled through friendly consultation
      between two parties hereto. Where the disputes cannot be settled through
      negotiations, it shall be prosecuted to the local court legally.

    Article
      21
      The two
      parties confirm that the relevant terms in the contract are as
      following:

    SDA
      :
      State Drug Administration.

    Article
      22 

    
      	
              1.

            	
              Technology
                evaluation report: None.

            

    

    
      	
              2.

            	
              Technology
                standard and regulation: None

            

    

    
      	
              3.

            	
              Initial
                design and technology documents:
                None.

            

    

    
      	
              4.

            	
              Other
                documents: None.

            

    

    Article
      23
      The two
      sides agree that other affairs not included in hereof shall be made into
      additional regulations through friendly consultation.

    Article
      24
      The
      contract shall be signed in sextuplicate. 

    Article
      25:
      The
      contract shall come into effect after the contract is made and signed by the
      Parties hereto.

    Party
      A

    Nantong
      Cyton Pharmaceutical Co., Ltd.

    Representative
      :

    

    Party
      B

    Nanjing
      Suji Bio-medicine Research and Development Co., Ltd.

    Representative:

    

    Date
      20
      January 2004

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00147-of-00352.parquet"}]]